Broad-spectrum antibiotic

Marrone Bio Innovations Partners with ATP Nutrition to Distribute Stargus® Biofungicide in Canada

Retrieved on: 
Thursday, June 3, 2021

We are very pleased to partner with ATP Nutrition; a best-in-class distributor with strong market share and a respected reputation with Canadian farmers, states Kevin Helash, chief executive officer of Marrone Bio Innovations.

Key Points: 
  • We are very pleased to partner with ATP Nutrition; a best-in-class distributor with strong market share and a respected reputation with Canadian farmers, states Kevin Helash, chief executive officer of Marrone Bio Innovations.
  • Stargus Biofungicide is a broad spectrum product with multiple modes of action powered by a novel, patented strain of formulated Bacillus bacteria.
  • The biofungicide effectively targets white mold and stalk rots caused by Sclerotinia, common diseases in some of the most dominant broad acre crops in Canada.
  • ATP Nutrition is a science-based company that focuses on the three key areas of production agriculture: plant nutrition, biostimulants (biologicals) and analytical tools.

Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia

Retrieved on: 
Tuesday, April 20, 2021

This may lead to significant side effects including severe damage to the gut epithelium, and major disruption to a patient\xe2\x80\x99s microbiome,\xe2\x80\x9d said Johan van Hylckama Vlieg, Chief Scientific Officer at Kaleido Biosciences.

Key Points: 
  • This may lead to significant side effects including severe damage to the gut epithelium, and major disruption to a patient\xe2\x80\x99s microbiome,\xe2\x80\x9d said Johan van Hylckama Vlieg, Chief Scientific Officer at Kaleido Biosciences.
  • \xe2\x80\x9cAdditionally, treatment combinations with broad-spectrum antibiotics used in the conditioning process, leave patients increasingly more susceptible to neutropenic fever.
  • These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect.
  • Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

Magnolia Medical Launches New "Diverted" Multi-Media Advertising Campaign to Educate Healthcare Providers on Benefits of Steripath®

Retrieved on: 
Wednesday, April 14, 2021

Unfortunately, up to half of the positive test results for sepsis are falsely positive due to blood sample contamination.\nThese high blood culture contamination rates are responsible for an estimated 1.4 million patients each year put at risk for unnecessary broad-spectrum antibiotic therapy, false-positive CLABSIs and extended hospital stays.

Key Points: 
  • Unfortunately, up to half of the positive test results for sepsis are falsely positive due to blood sample contamination.\nThese high blood culture contamination rates are responsible for an estimated 1.4 million patients each year put at risk for unnecessary broad-spectrum antibiotic therapy, false-positive CLABSIs and extended hospital stays.
  • This movement was initiated by the call-to-action from the authors of a multi-discipline consensus manuscript published in Clinical Microbiology Reviews in January 2020.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Initial Specimen Diversion Device (ISDD) for blood culture collection and contamination prevention.
  • The company has amassed an intellectual property portfolio including more than 80 issued method, apparatus and design patents with more than 70 additional patent applications pending.

Crestone, Inc. (Boulder) Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate

Retrieved on: 
Thursday, September 12, 2019

Under this contract, the safety and efficacy of CRS3123 will be evaluated for the first time in patients with CDI.

Key Points: 
  • Under this contract, the safety and efficacy of CRS3123 will be evaluated for the first time in patients with CDI.
  • CDI is the leading cause of antibiotic-associated diarrhea among hospitalized patients and is becoming more prevalent in the community, including in younger patients.
  • Currently, most patients are treated with suboptimal, broad-spectrum antibiotics that prevent healthy gut microbiota from recovering, contributing to CDI recurrence rates of 20-40%.
  • Funding for this trial will be provided entirely by NIHs National Institute of Allergy and Infectious Diseases (NIAID) under Contract No.

New Intermountain Study Finds Overuse of Broad-Spectrum Antibiotic Treatment for Pneumonia Leads to Worse Outcomes

Retrieved on: 
Tuesday, July 30, 2019

More than 250,000 people in the nation seek care at emergency rooms every year due to pneumonia.

Key Points: 
  • More than 250,000 people in the nation seek care at emergency rooms every year due to pneumonia.
  • Antibiotics are an important part of pneumonia treatment and target the most common bacteria that cause this infection.
  • However, researchers found that using broad-spectrum antibiotics to treat pneumonia works against drug-resistant bacteria that less commonly cause pneumonia, said Dr. Webb.
  • In the study, researchers identified 1,995 adults who came to four Intermountain Healthcare hospital emergency rooms with community onset pneumonia, which means they didnt develop pneumonia while they were in the hospital.

New Intermountain Study Finds Overuse of Broad-Spectrum Antibiotic Treatment for Pneumonia Results in Poorer Outcomes

Retrieved on: 
Tuesday, July 30, 2019

More than 250,000 people in the nation seek care at emergency rooms every year due to pneumonia.

Key Points: 
  • More than 250,000 people in the nation seek care at emergency rooms every year due to pneumonia.
  • Antibiotics are an important part of pneumonia treatment and target the most common bacteria that cause this infection.
  • However, researchers found that using broad-spectrum antibiotics to treat pneumonia work against drug-resistant bacteria that less commonly cause pneumonia, said Dr. Webb.
  • In the study, researchers identified 1,995 adults who came to four Intermountain Healthcare hospital emergency rooms with community onset pneumonia, which means they didn't develop pneumonia while they were in the hospital.

FIU scientists discover new arsenic-based broad-spectrum antibiotic

Retrieved on: 
Tuesday, April 16, 2019

MIAMI, April 16, 2019 /PRNewswire/ --Antibiotic resistance has been called one of the biggest public health threats of our time.

Key Points: 
  • MIAMI, April 16, 2019 /PRNewswire/ --Antibiotic resistance has been called one of the biggest public health threats of our time.
  • Researchers from FIU's Herbert Wertheim College of Medicine are part of an international team that has discovered a new broad-spectrum antibiotic that contains arsenic.
  • "Arsinothricin is the first and only known natural arsenic-containing antibiotic, and we have great hopes for it."
  • We need a new potent antibiotic to solve this problem," says Yoshinaga, the other co-senior author.

HKBU Scholars Invent World-First Multidimensional System for Rapid Antibiotic Resistance Testing and Analysis

Retrieved on: 
Thursday, January 17, 2019

Researchers from the Department of Chemistry at Hong Kong Baptist University (HKBU) have invented the world's first multidimensional antimicrobial susceptibility testing (AST) system.

Key Points: 
  • Researchers from the Department of Chemistry at Hong Kong Baptist University (HKBU) have invented the world's first multidimensional antimicrobial susceptibility testing (AST) system.
  • The system is simple to operate and only requires a small amount of the patient's body fluid, such as blood or saliva.
  • After about four hours, the system indicates the effectiveness of the antibiotic treatment and whether it is needed.
  • This broad-spectrum approach can also kill harmless bacteria, accelerating antibiotic resistance in pathogens and affecting the long-term health of patients.

HKBU Scholars Invent World-First Multidimensional System for Rapid Antibiotic Resistance Testing and Analysis

Retrieved on: 
Thursday, January 17, 2019

Researchers from the Department of Chemistry at Hong Kong Baptist University (HKBU) have invented the world's first multidimensional antimicrobial susceptibility testing (AST) system.

Key Points: 
  • Researchers from the Department of Chemistry at Hong Kong Baptist University (HKBU) have invented the world's first multidimensional antimicrobial susceptibility testing (AST) system.
  • The system is simple to operate and only requires a small amount of the patient's body fluid, such as blood or saliva.
  • After about four hours, the system indicates the effectiveness of the antibiotic treatment and whether it is needed.
  • This broad-spectrum approach can also kill harmless bacteria, accelerating antibiotic resistance in pathogens and affecting the long-term health of patients.

OsteoRemedies® Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin

Retrieved on: 
Thursday, November 1, 2018

Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY SPECTRUM GV Hip System will provide surgeons with the first ever broad-spectrum treatment option with both Gentamicin and Vancomycin.

Key Points: 
  • Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY SPECTRUM GV Hip System will provide surgeons with the first ever broad-spectrum treatment option with both Gentamicin and Vancomycin.
  • "We are very proud to have the first FDA cleared dual-antibiotic spacer system and bone cement offering," stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies.
  • SPECTRUM GV Bone Cement is indicated for use with the REMEDY SPECTRUM GV Hip Spacer System.
  • Other product offerings include OSTEOBOOST RBK and FLORASEAL Microbial Sealant and UNITE AB Bone Cement.